The Chinese biopharmaceutical contract manufacturing market is anticipated to be worth USD 2.6 Billion by 2030, growing at an annualized rate of 12.7%, claims Roots Analysis

Reduced manufacturing costs, availability of cheap and skilled labor and a supportive regulatory landscape in China has compelled various biopharmaceutical developers across the globe to outsource their manufacturing operations to this region

Roots Analysis has announced the addition of the China Biologics Contract Manufacturing Market report to its list of offerings. 

Further, China’s large population, coupled to high capital investments and innovation-friendly environment, is anticipated to drive the growth of the China biopharmaceutical contract manufacturing market. In order to meet the growing demand for their services, Chinese CMOs are actively consolidating / expanding their capabilities through partnerships and / or dedicated expansion initiatives.   

To order this 250+ page report, which features 100+ figures and 120+ tables, please visit https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/313.html

Key Market Insights 

Around 40 Chinese CMOs claim to offer manufacturing services for biopharmaceuticals 

The biopharmaceutical contract manufacturing market in China is currently dominated by the presence of small and mid-sized companies, which represent 67% of stakeholders in this industry. It is also worth highlighting that 77% of the CMOs engaged in this domain claim to have the required capabilities for manufacturing proteins / peptide drugs.

Eastern China is considered to be one of the key manufacturing hubs for biopharmaceuticals

Majority of Chinese biopharmaceutical service providers (46%) claim to have facilities in the this part of the country. Of these, 16 players report having the required capabilities to manufacture biopharmaceuticals at the commercial scale. Further, the annual, installed capacity for biopharmaceutical manufacturing in Eastern China is estimated to be around 0.16 million L. 

75+ partnerships were established in this domain, between 2016-2020 (till February)

Interestingly, around 66% of reported deals were established after 2017, while maximum partnership activity was observed in 2018. Further, majority of the agreements (21%) signed within this domain were observed to be focused on the development and manufacturing of biopharmaceutical products.

Since 2014, several expansion initiatives were undertaken by Chinese biopharmaceutical CMOs 

More than 75% of such initiatives, reported during the period 2016-2020 (till February), were focused on the establishment of new facilities. This was followed by expansion of biopharmaceutical manufacturing related capabilities (7%). It is worth noting that over 75% of the total number of expansions were centered in the Asia-Pacific; of these, 90% were carried out in China based facilities.

Over 1,500 clinical trials of biological interventions conducted / underway in China

Till date, these studies have recruited / dosed more than 1.4 million patients, in the region. It is worth mentioning that majority of the aforementioned patients (0.5 million) were recruited in trial sites located in Taiwan. The increasing number of clinical trials is likely to result in a rise in the demand for biopharmaceutical manufacturing services in the region. 

Active involvement of big pharma players in biologic-related initiatives in China 

It is worth noting that over 65% of such initiatives were undertaken post 2010; of these, 53% were observed to be partnerships signed between big pharma players and China based biopharmaceutical developers and manufacturers. Further, 15% of the big pharma initiatives were reported to be focused on vaccines.

By 2030, biologics produced using mammalian systems are anticipated to capture more than 70% share (in terms of service revenue) of the China biopharmaceutical contract manufacturing market 

Owing to the recent COVID-19 pandemic, an increase in the development initiatives carried out for biopharmaceuticals is likely to be witnessed in the near future. This is further expected to result in a rise in the overall demand for biopharmaceutical contract manufacturing services across the globe, specifically in China. 

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/request-sample.html

Key Questions Answered

• Who are the leading biopharmaceutical contract manufacturers in China?
• What is the annual clinical demand for biopharmaceuticals in China?
• What is the current installed capacity for manufacturing biopharmaceuticals in China?
• What kind of partnership models are commonly adopted by stakeholders engaged in this domain?
• What were the various expansion initiatives carried out by Chinese biopharmaceutical CMOs?
• What were the different biopharmaceutical focused initiatives undertaken by big pharma players in the recent past, in China? 
• How is the current and future market opportunity likely to be distributed across key market segments? 

The USD 2.6 billion (by 2030) financial opportunity within the China biopharmaceutical contract manufacturing market has been analyzed across the following segments:

• Type of Product
  • API
  • FDF
• Type of Expression System Used 
  • Mammalian 
  • Microbial 
  • Others 
• Scale of Operation
  • Preclinical / Clinical 
  • Commercial 
• Size of Manufacturer 
  • Small 
  • Mid-sized 
  • Large / Very Large 
• Type of Biologic
  • Antibody
  • Vaccine 
  • Others 

The report features inputs from eminent industry stakeholders, according to whom emerging markets, such as China, are anticipated to witness a significant increase in the overall demand of biopharmaceuticals in the near future. The report includes detailed transcripts of discussions held with the following experts:

• Stephen Taylor (Senior Vice President Commercial, FUJIFILM Diosynth Biotechnologies)
• Jeffrey Hung (Chief Commercial Officer, Vigene Biosciences)
• Birgit Schwab (Senior Manager Strategic Marketing, Rentschler Biopharma)

The research covers detailed profiles of key stakeholders (listed below); each profile features an overview of the company, its financial information (if available), details related to its service portfolio, manufacturing facilities, recent developments and an informed future outlook.

• ChemPartner Biologics 
• JHL Biotech
• JOINN Biologics
• MabPlex
• Mycenax Biotech
• WuXi AppTec

For additional details, please email at sales@rootsanalysis.com 

Contact:

Gaurav Chaudhary
Gaurav.Chaudhary@rootsanalysis.com